ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Recurrence"

  • 2016 American Transplant Congress

    Clinical Analysis of Patients with Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation.

    D. Kim, G. Na, T. Hong, Y. You.

    Surgery, Seoul St. Mary's Hospital, Catholic University, Seoul, Korea.

    Purpose: For living-donor liver transplantation (LDLT), there has been a tendency to accept extended criteria in comparison with deceased-donor liver transplantation (DDLT). However, HCC recurrence…
  • 2016 American Transplant Congress

    Selection of Patients with Solitary Lesion of Hepatocellular Cancer for Liver Transplantation.

    M. Grąt,1 J. Stypułkowski,1 W. Patkowski,1 K. Wronka,1 M. Wasilewicz,2 K. Grąt,3 L. Masior,1 M. Krasnodębski,1 Z. Lewandowski,4 M. Krawczyk.1

    1Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland; 2Department of General, Transplant and Liver Surgery, Liver and Internal Medicine Unit, Medical University of Warsaw, Warsaw, Poland; 3Second Department of Clinical Radiology, Medical University of Warsaw, Warsaw, Poland; 4Department of Epidemiology, Medical University of Warsaw, Warsaw, Poland.

    Milan criteria are considered as benchmark for selection of patients with hepatocellular cancer (HCC) for liver transplantation. The aim of this study was to evaluate…
  • 2016 American Transplant Congress

    Which Is the Predictable Values of Post-Transplant Hepatocellular Carcinoma Recurrence in Patients Received Down Staging Therapy or Bridging Therapy?

    S. Song, J. Lee, S.-K. Kwon, J. Lee, J. Lee, D. Han, G. Choi, M. Kim, J. Choi, S. Kim, D. Joo.

    Department of Surgery and The Research Institute for Transplantation, Yonsei University College of Medicine, Seoul, Korea.

    Introduction: Liver transplantation (LT) is one of the best treatment for small hepatocellular carcinoma (HCC) in patients with liver cirrhosis. However, many patients do not…
  • 2016 American Transplant Congress

    Clinical Usefulness of mRECIST Response to Chemoembolization for Recurrence Prediction of Hepatocellular Carcinoma in Living Donor Liver Transplantation.

    C. Cho, K. Kim, S. Kim, J. Lee, J. Lee, J. Kim, G.-S. Choi, C. Kwon, J.-W. Joh, N. Lee.

    Surgery, Samsung Medical Center, Seoul, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

    Background Predicting risk for recurrence of hepatocellular carcinoma (HCC) following living donor liver transplantation (LDLT) is clinically important.Methods We performed a retrospective study for assessment…
  • 2015 American Transplant Congress

    Focal Segmental Glomerulosclerosis Recurrence in Renal Transplant Recipients Treated With Belatacept

    W. Kitchens,1 A. Farris,2 S. Pastan,1 T. Pearson,1 C. Larsen,1 A. Adams.1

    1Emory Transplant Center, Atlanta, GA; 2Department of Pathology, Emory University Hospital, Atlanta, GA.

    Introduction: Focal segmental glomerulosclerosis (FSGS) is a cause of end-stage renal failure that frequently recurs following renal transplant, often leading to early allograft loss. A…
  • 2015 American Transplant Congress

    The use of Donation After Cardiac Death Liver Allografts does not increase Recurrence of Hepatocellular Carcinoma

    K. Croome, D. Lee, J. Burns, J. Nguyen, D. Perry, D. Harnois, C. Taner.

    Transplant, Mayo Clinic, Jacksonville, FL.

    Background: Previous studies examining the Scientific Registry of Transplant Recipients (SRTR) database for liver transplantation (LT) have demonstrated inferior survival for hepatocellular carcinoma (HCC) recipients…
  • 2015 American Transplant Congress

    Pretransplant Elevated Plasma Fibrinogen Level Is Associated With Tumor Recurrence and Poor Prognosis in Hepatocellular Carcinoma Patients After Liver Transplantation

    G.-Y. Wang, Y. Yang, H. Li, S.-H. Yi, G.-H. Chen.

    Department of Hepatic Surgery and Liver Transplant Center, Third Affiliated Hospital, Sun Yat-sen University, Organ Transplantation Institution of Sun Yat-sen University, Guangzhou, China.

    Background and Objective: Elevated plasma fibrinogen (FBG) level is associated with tumor progression and poor patient outcomes in several cancers. The aim of this study…
  • 2015 American Transplant Congress

    Associations Between Sirolimus Use and Outcomes After Liver Transplant for Hepatocellular Carcinoma

    E. Yanik,1 S. Chinnakotla,2 A. Israni,2,3 J. Snyder,2,3 S. Gustafson,3 E. Engels.1

    1Natl. Cancer Inst., Bethesda, MD; 2U. of Minnesota, Minneapolis, MN; 3Sci. Reg. of Transplant Recipients, Minneapolis, MN.

    A growing fraction of U.S. liver transplants are being done for the indication of hepatocellular carcinoma (HCC). HCC recurrence after transplant remains a major concern…
  • 2015 American Transplant Congress

    Predictors of Time to Recurrence and Mortality Associated With Recurrent Hepatocellular Carcinoma After Liver Transplantation

    A. Bodzin, D. Reino, K. Lunsford, M. Harlander-Locke, D. Markovich, A. Zarrinpar, F. Kaldas, D. Farmer, R. Busuttil, V. Agopian.

    Transplantation, UCLA, Los Angeles, CA.

    Background: While recurrent hepatocellular carcinoma (HCC) after liver transplantation (LT) portends a poor prognosis, adjuvant therapy may prolong survival. We sought to identify factors that…
  • 2015 American Transplant Congress

    Recurrence of Hepatocellular Carcinoma After Transarterial Chemoembolization (TACE) Alone and TACE in Combination With Other Treatment Modalities

    J. Balogh, A. Islam, A. Saharia, H. Monsour, S. Gordon Burroughs, M. Weiner, A. Gaber, R. Ghobrial.

    General Surgery, Houston Methodist Hospital, Houston, TX.

    AIM:Treatment of hepatocellular carcinoma (HCC) with transarterial chemoembolization (TACE) can help downstage tumors prior to orthotopic liver transplantation (OLT); however, there is a risk of…
  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences